Kura Oncology, Inc. — FY2021 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2021. The filing is an annual Form 10-K rather than a standalone fourth-quarter report. Kura is a clinical-stage oncology company with no approved products and no product revenue. Its pipeline includes clinical-stage ziftomenib and tipifarnib, preclinical-stage KO-2806, and discovery programs.
Business Context and Pipeline
- Ziftomenib: Oral menin-KMT2A inhibitor being evaluated in relapsed or refractory AML in the KOMET-001 Phase 1/2 trial, including NPM1-mutant and KMT2A-rearranged disease.
- Tipifarnib: Farnesyl transferase inhibitor being evaluated in HRAS-mutant head and neck squamous cell carcinoma, peripheral T-cell lymphomas and combination studies.
- KO-2806: Next-generation farnesyl transferase inhibitor in IND-enabling studies; management expected to submit an IND by the end of 2022.
- The company owns global commercial rights to its programs and relies on third parties for clinical research, manufacturing and companion diagnostics.
Financial Performance and Position
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Product revenue | $0 | $0 | No change |
| Research and development expense | $84.7 million | $60.4 million | +$24.3 million |
| General and administrative expense | $46.5 million | $31.5 million | +$15.0 million |
| Total operating expenses | $131.3 million | $91.9 million | +$39.4 million |
| Other income, net | $0.8 million | $2.3 million | -$1.5 million |
| Net loss | $130.5 million | $89.6 million | Loss increased $40.8 million |
| Net loss per share | $1.97 | $1.69 | Loss per share increased |
| Net cash used in operating activities | $104.6 million | $69.8 million | Use increased $34.7 million |
Operating and net margins are not meaningful because the company has no product revenue. Share-based compensation expense was $23.6 million in 2021, compared with $12.8 million in 2020, including $7.5 million in research and development and $16.1 million in general and administrative expense.
- Cash, cash equivalents and short-term investments totaled $518.0 million at December 31, 2021, consisting of $90.7 million in cash and cash equivalents and $427.3 million in short-term investments.
- Total assets were $534.1 million and total stockholders’ equity was $506.6 million.
- The company repaid its remaining term loan in May 2021. No long-term debt remained at year-end.
- Management stated that existing cash, cash equivalents and short-term investments should fund operating expenses and capital requirements into 2024, based on current plans.
- The company had an accumulated deficit of $433.0 million and expects continuing operating losses and negative operating cash flow.
- Operating lease payments totaled $7.5 million through 2025, including $2.3 million due within one year. Potential milestone payments under license agreements total approximately $80.2 million, plus sales-based royalties, if specified events occur.
Material Changes Versus 2020
- R&D spending increased 40%, driven primarily by higher ziftomenib clinical and manufacturing costs, tipifarnib clinical and companion-diagnostic activities, discovery programs and personnel.
- G&A spending increased 48%, primarily due to higher share-based compensation, personnel costs, and professional and legal services.
- Cash operating burn increased substantially, while investing cash use rose to $126.8 million because of increased purchases of marketable securities.
- Financing cash flow changed from $469.3 million of inflows in 2020, largely from public stock offerings, to $3.4 million of outflows in 2021. The 2021 outflow principally reflected repayment of debt, partially offset by employee stock option and stock purchase proceeds.
- Common shares outstanding increased from 66.2 million at December 31, 2020 to 66.6 million at December 31, 2021. The company had not used its $75.0 million at-the-market equity facility.
- Headcount increased to 121 full-time employees at year-end, with 73 in research, development and supply chain and 48 in commercial and general and administrative functions.
Guidance, Outlook, Risks and Unusual Items
- The FDA placed the KOMET-001 trial on partial clinical hold on November 24, 2021 after a Grade 5 serious adverse event potentially associated with differentiation syndrome. The hold was lifted on January 20, 2022 after agreement on a mitigation strategy.
- Management expected to complete enrollment in the KOMET-001 Phase 1b expansion cohorts in the second quarter of 2022 and identify the recommended Phase 2 dose and report topline data in the third quarter of 2022.
- COVID-19 continued to slow clinical-site activation, patient screening and enrollment, particularly for the AIM-HN tipifarnib trial. Management could not reasonably forecast when AIM-HN would be fully enrolled.
- Tipifarnib received FDA Breakthrough Therapy Designation for recurrent or metastatic HRAS-mutant HNSCC with variant allele frequency of at least 20% after progression on platinum-based chemotherapy.
- The KURRENT Phase 1/2 combination study of tipifarnib and Novartis’s alpelisib began dosing its first patient in December 2021. Kura supplies tipifarnib and sponsors the study; Novartis supplies alpelisib.
- Key risks include failure or delay of clinical trials, safety events, difficulty identifying biomarker-defined patients, dependence on companion diagnostics, third-party manufacturers and CROs, regulatory uncertainty, competition, intellectual-property challenges and the need for additional capital.
- The company has no committed external source of financing. Additional equity, debt, collaboration or licensing financing may be dilutive, restrictive or unavailable on acceptable terms.
- Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting. The critical audit matter concerned estimation of accrued third-party clinical-trial R&D expenses.
Most Important Facts for Investors to Verify
- Whether KOMET-001 enrollment, recommended-dose selection and topline reporting occurred on the projected 2022 timeline following the clinical hold.
- Whether differentiation syndrome and other adverse events affect ziftomenib’s dose, labeling, development path or registrational prospects.
- Progress, enrollment and independently assessed efficacy results for the AIM-HN tipifarnib trial, rather than relying solely on earlier investigator-assessed RUN-HN results.
- Whether the Illumina companion diagnostic and other biomarker-testing arrangements obtain required regulatory approval and sufficient reimbursement.
- Actual cash burn and remaining liquidity relative to management’s projection of funding into 2024.
- Potential dilution from future financings, equity awards, options, restricted stock units, warrants and the unused $75.0 million ATM facility.
- Future milestone and royalty obligations under the University of Michigan, Janssen and other license agreements.